Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pituitary adenylate cyclase-activating polypeptide-38
- Development stage
- Phase 1
- Lead developer
- Lundbeck
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) is a 38-amino acid endogenous neuropeptide that acts as a potent agonist at the PAC1, VPAC1, and VPAC2 receptors. In clinical research conducted by the Danish Headache Center, PACAP-38 is utilized as a pharmacological provocation tool to experimentally induce migraine attacks, including migraine with aura, in susceptible individuals. Administered via intravenous infusion, PACAP-38 triggers a cascade of physiological responses, including vasodilation and activation of the trigeminovascular system, which mimics naturally occurring migraine pathophysiology. This experimental model is crucial for investigating migraine mechanisms and evaluating the efficacy of novel therapeutic candidates targeting the PACAP pathway, such as anti-PACAP antibodies.
- Other names
- PACAP38PACAP-38PACAP 38pituitary adenylate cyclase-activating polypeptide 38
02
Targets
ADCYAP1R1 (Pituitary adenylate cyclase-activating polypeptide receptor PAC1)VIPR2 (Vasoactive intestinal polypeptide receptor 2)VIPR1 (Vasoactive intestinal peptide receptor 1)
Beyond the preview
Go deeper on pituitary adenylate cyclase-activating polypeptide-38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pituitary adenylate cyclase-activating polypeptide-38.